首个获得批准的登革热疫苗CYD-TDV(Dengvaxia)在血清阳性者中是有效的,但血清阴性者接种后却增加了严重登革热的风险.因此,对于考虑引入Dengvaxia的国家,WHO建议采取疫苗接种前筛查策略,仅对有既往登革热感染证据的人群接种疫苗.2019年1月,全球登革热和伊蚊传播疾病联合会在法国安纳西组织召开了为期3 d的研讨会,来自亚洲...
登革热疫苗筛查快速诊断试验首个获得批准的登革热疫苗CYD-TDV(Dengvaxia)在血清阳性者中是有效的,但血清阴性者接种后却增加了严重登革热的风险.因此,对于考虑引入Dengvaxia的国家,WHO建议采取疫苗接种前筛查策略,仅对有既往登革热感染证据的人群接种疫苗.2019年1月,全球登革热和伊蚊传播疾病联合会在法国安纳西组织召开了为期...
The first licensed dengue vaccine, CYD-TDV (Dengvaxia) is efficacious in seropositive individuals, but increases the risk for severe dengue in seronegative persons about two years after administration of the first dose. For countries considering the introduction of Dengvaxia, WHO recommends a pre-...
The value of multi-country joint regulatory reviews: the experience of a WHO joint technical consultation on the CYD-TDV (Dengvaxia(R)) dossier. Vaccine. 2017 Oct 13;35(43):5731-5733. doi:10.1016/j.vaccine.2017.07.044.Vannice K, Chocarro L, Pfleiderer M, Bellah A, Ward M, Yoon I-K...